SABCS: Active Monitoring Noninferior to Guideline Care for Ductal Carcinoma in Situ
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 13, 2024 -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) that involves surgery with or without adjuvant radiation, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.
E. Shelley Hwang, M.D., M.P.H., from the Duke University School of Medicine in Durham, North Carolina, and colleagues examined the outcomes of 995 participants with grade 1 or 2 hormone receptor-positive, human epidermal growth factor receptor 2-negative DCIS enrolled in the Comparing an Operation to Monitoring, with or without Endocrine Therapy for low risk DCIS trial who were randomly assigned to GCC (473 patients) or AM (484 patients). Participants in the AM group underwent surgical intervention only upon invasive progression diagnosis, or they could elect to have surgery at any time. Patients were allowed to receive endocrine therapy if desired, in both treatment arms.
The researchers found that 27 patients in the GCC arm and 19 in the AM arm had been diagnosed with invasive ipsilateral breast cancer after 24 months of follow-up. The two-year cumulative rate of invasive ipsilateral breast cancer was 5.9 and 4.2 percent for the GCC and AM arms, respectively, meeting the threshold for noninferiority. More patients in the AM versus GCC arm received endocrine therapy (71.3 versus 65.5 percent). Of those receiving endocrine therapy, invasive ipsilateral cancer was seen in 7.15 percent of patients in the GCC arm and 3.21 percent in the AM arm.
"Omission of surgery has been highly controversial, with both patients and providers fearing that it might result in an unacceptably high rate of patients who develop invasive cancer," Hwang said in a statement. "Our findings are reassuring, and longer-term follow up will have important implications for the future inclusion of active monitoring as a treatment option for low-risk DCIS."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
2005 to 2019 Saw Increase in Incidence of Cervical Artery Dissection
FRIDAY, April 4, 2025 -- Cervical artery dissection (CeAD) incidence increased from 2005 to 2019, with the increase in admissions particularly high in older, Black, and Hispanic...
Greater Wealth Linked to Lower Mortality, With Stronger Link in U.S.
FRIDAY, April 4, 2025 -- Greater wealth is associated with lower mortality, and the association seems stronger in the United States than in Europe, according to a study published...
Study Quantifies Breast Shrinkage After T1 Tumor Lumpectomy
FRIDAY, April 4, 2025 -- Patients with T1 tumors undergoing breast-conserving therapy/radiation therapy (BCT/RT) may lose about 20 percent of breast volume at one year, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.